**Efficacy, safety, and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled trial (CAP-IT)**

*Authors*

Mark D Lyttle1,2, Julia Bielicki3, Sam Barratt4, David Dunn4,Adam Finn5, Lynda Harper4,Pauline Jackson1,Colin VE Powell6,7, Damian Roland8,9, Wolfgang Stöhr4, Kate Sturgeon4,Mandy Wan10, Paul Little11, Saul N Faust11,12, Julie Robotham13, Alastair D Hay14, Diana M Gibb4\*, Mike Sharland3\*

And PERUKI, GAPRUKI and the CAP-IT trial team

*Affiliations*

1. Emergency Department, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol, UK
2. Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK
3. Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George’s University of London, MRC Clinical Trial Unit at UCL, London, UK
4. MRC Clinical Trials Unit at UCL, 90 High Holborn, London, UK
5. Bristol Children’s Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, UK
6. Paediatric Emergency Medicine Department, Sidra Medicine, Doha, Qatar
7. School of Medicine, Cardiff University , Cardiff UK
8. Paediatric Emergency Medicine Leicester Academic (PEMLA) group, Leicester Hospitals, Leicester, UK
9. SAPPHIRE group, Health Sciences, Leicester University, Leicester, UK
10. NIHR CRN: Children, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
11. Faculty of Medicine, University of Southampton, Southampton, UK
12. NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
13. HCAI & AMR Division, National Infection Service, Public Health England, UK
14. Centre for Academic Primary Care, Bristol Medical School: Population Health Sciences, University of Bristol

\*These authors contributed equally to this work

*Protocol Version 4.0, 4th December 2018*

*Word count:* 3932

*Keywords***:** Community acquired pneumonia; children; amoxicillin; antibiotic treatment

*Corresponding author*

Mark Lyttle

Emergency Department

Bristol Royal Hospital for Children

Upper Maudlin Street

Bristol

United Kingdom

BS2 8BJ

Email: [mdlyttle77@gmail.com](mailto:mdlyttle77@gmail.com)

Phone: 07788185454

**ABSTRACT**

**Introduction**

Community acquired pneumonia (CAP) is a common indication for antibiotic treatment in young children. Data are limited regarding the ideal dose and duration of amoxicillin, leading to practice variation which may impact on treatment failure and antimicrobial resistance (AMR). Community Acquired Pneumonia: a randomIsed controlled Trail (CAP-IT) aims to determine optimal amoxicillin treatment strategies for CAP in young children in relation to efficacy and AMR.

**Methods and analysis**

The CAP-IT trial is a multi-centre randomised double blind placebo-controlled 2x2 factorial non-inferiority trial of amoxicillin dose and duration. Children are enrolled in paediatric emergency and inpatient environments, and randomised to receive amoxicillin 70-90 mg/kg/day or 35-50 mg/kg/day for three or seven days following hospital discharge. The primary outcome is systemic antibacterial treatment for respiratory tract infection (including CAP) other than trial medication up to four weeks after randomisation. Secondary outcomes include adverse events, severity and duration of parent-reported CAP symptoms, adherence, and antibiotic resistance. The primary analysis will be by intention-to-treat. Assuming a 15% primary outcome event rate, 8% non-inferiority margin assessed against an upper one-sided 95% confidence interval, 90% power, and 15% loss to follow-up, 800 children will be enrolled to demonstrate non-inferiority for the primary outcome for each of duration and dose.

**Ethics and dissemination**

The CAP-IT trial and relevant materials were approved by the National Research Ethics Service (Reference: 16/LO/0831; 30th June 2016). The CAP-IT trial results will be published in peer-reviewed journals, and in a report published by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme. Oral and poster presentations will be given to national and international conferences, and participating families will be notified of the results if they so wish. Key messages will be constructed in partnership with families, and social media will be utilised in their dissemination.

**Trial registration**

ISRCTN identifier: ISRCTN76888927 (15/12/2015)

EudraCT identifier: 2016-000809-36 (22/02/2016)

**Strengths and limitations of this trial**

* This well powered multicentre trial will provide new data on efficacy of amoxicillin treatment strategies for uncomplicated community acquired pneumonia in young children in developed settings in the post pneumococcal vaccine era
* The CAP-IT trial is one of few randomised controlled trials to measure the impact of differing antibiotic treatment regimens on antimicrobial resistance
* The pragmatic approach to eligibility employed by the CAP-IT trial is aligned with clinical practice and so will facilitate rapid knowledge translation
* Although determining the optimal endpoint for pragmatic trials is challenging, use of an endpoint review committee in the CAP-IT trial will strengthen the confidence in the results
* The generalisability of the CAP-IT trial findings will be maximised by the diversity of the enrolled population, in both severity and setting

**INTRODUCTION**

Acute respiratory infections (including community-acquired pneumonia; CAP) are the most common indication for childhood antibiotic use in primary care and emergency departments (ED).[1-3] Up to 40% of preschool children attend primary care for acute respiratory symptoms, with antibiotics prescribed in 30%.[3,4] One third of childhood ED visits are for acute respiratory symptoms or fever; up to 15% are diagnosed with CAP, with highest antibiotic prescription rates in those aged <5 years.[5-7] ED attendances and hospital admissions for respiratory illness in young children increase annually, and two-thirds of antibiotics for hospitalised 1-5 year olds are for CAP.[5,8,9] The healthcare cost of childhood CAP in England is estimated at £8 million/year, though total annual societal costs are up to £17 million.[10,11]

CAP is a differential diagnosis in any child presenting with fever, respiratory symptoms, and focal chest signs. No gold standard laboratory, microbiological or radiological tests distinguish bacterial from viral infection; diagnosis and treatment decisions are based on clinical criteria.[12-14] *Streptococcus pneumoniae* is the most commonly implicated bacterial pathogen, even in settings with routine pneumococcal vaccination (PCV).[15-17] Children have high rates of bacterial colonisation and carriage of resistant organisms which may be transmitted, with particular risks for vulnerable individuals.[18-21] Interventions to maintain low antimicrobial resistance (AMR) levels in children may therefore have wider benefits.

Amoxicillin is the recommended antibiotic for childhood CAP in several international guidelines;[12,22-24] however there are insufficient data to inform dose, duration, and impact on AMR. The British National Formulary for Children (BNFc) recommends amoxicillin thrice daily at 40-80mg/kg/day. Twice daily dosing is widely recommended due to improved adherence and non-inferiority, including by the World Health Organisation (WHO).[22-26] Shorter treatment courses are effective in trials performed in low and middle income country (LMIC) settings, though diagnostic and eligibility criteria limit generalisability of findings.[27,28] Trials from developed settings pre-date PCV or include populations with high penicillin resistance rates. There are therefore no robust data to inform treatment duration, leading to variation between three and seven days.[23,24,27-30] Assessment of treatment efficacy is challenging, as only half of patients recover after ten days, and 90% take up to four weeks to recover fully.[4,31,32] Whilst ongoing “minimal” symptoms may trigger retreatment (deemed treatment failure) relatively frequently, the most widely used efficacy measure is re-exposure to antibiotics for up to four weeks, with recent reported rates of 15%.[29,31,33]

The impact of antibiotics on colonisation with resistant bacteria is complex and dynamic.[34-37] Insufficiently high dosing could promote selection of resistant pathogens, and while the greatest effect on bacterial load is achieved early, resistant isolates emerge after 4-5 days.[38,39] Combined effectiveness and resistance data related to antibiotic dose and duration would inform antimicrobial stewardship and childhood CAP treatment strategies.

The CAP-IT trial will evaluate efficacy, safety, and effect on AMR of different durations and doses of oral amoxicillin treatment for young children with uncomplicated CAP. The specific primary objectives are to determine whether (i) three days is non-inferior to seven days, and (ii) 35-50mg/kg/day is non-inferior to 70-90mg/kg/day.

**METHODS**

This multi-centre randomised double blind placebo-controlled 2x2 factorial non-inferiority trial aims to enrol 800 patients over two years. Amoxicillin dose and duration are assigned simultaneously, resulting in four treatment arms (Figure 1). This protocol has been written in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist (Additional File 1).[40]

**Patient and public involvement**

Parents of young children have been involved throughout the development and delivery of the CAP-IT trial. In developing the research question, they advised that shorter antibiotic courses would be welcomed if equally effective, due to difficulties in giving medicine (due to palatability, or challenges with daycare and daytime doses). For the same reasons, parents supported twice daily dosing. A key need identified during trial development was support for families, including clear symptomatic safety netting, close contact, and availability of a contact number for the local research and clinical teams. Parents reviewed and provided input on all information materials to ensure they were clear and easy to understand. The CAP-IT Trial Steering Committee has a parent member, who contributes to discussions as the trial progresses, and will advise on best methods of disseminating results to families as we approach the analysis phase.

**Trial setting**

Sites throughout the UK and Ireland are participating, from Paediatric Emergency Research in the UK & Ireland (PERUKI; [www.peruki.org](http://www.peruki.org)),[41] and General & Adolescent Paediatric Research in the UK & Ireland (GAPRUKI; [www.gapruki.org.uk](http://www.gapruki.org.uk)). Participating sites are tertiary or secondary hospitals with EDs and inpatient areas where potentially eligible children are managed; participating centres are listed on the trial website ([www.capitstudy.org.uk](http://www.capitstudy.org.uk)). Centres are selected based on research infrastructure, likely number of recruits, participation in feasibility work, and proposed training strategies. Site Principal Investigators (PI) are qualified by education, training and experience to assume responsibility for proper conduct of the trial.

**Trial population**

Participants may be enrolled from EDs, observation units, paediatric assessment units (PAU), or inpatient wards, provided they fulfil eligibility criteria.

***Inclusion criteria***

Children are eligible if they are aged ≥6 months, weigh 6-24kg, have a clinical diagnosis of CAP (Box 1) and will be treated with amoxicillin as the sole antibacterial agent on hospital discharge. Children must have received none or less than 48 hours of treatment with only beta-lactam antibiotics at enrolment.

***Exclusion criteria***

Children are ineligible if they have (i) severe underlying chronic disease (including sickle cell anaemia, immunodeficiency, chronic lung disease, cystic fibrosis), (ii) penicillin allergy or other contra-indication to amoxicillin, (iii) complicated pneumonia (shock, hypotension, altered mental state, ventilatory support, empyema, pneumothorax, pulmonary abscess), or (iv) bilateral wheezing without focal chest signs.

***Box 1: Definition of clinical diagnosis of CAP***

|  |
| --- |
| *Clinical diagnosis of CAP is defined as all**of the following*:   1. Cough (reported by parents/guardians within 96 hours before presentation) AND 2. Temperature ≥38°C measured by any method OR reported fever within 48 hours before presentation AND 3. Signs of laboured/difficult breathing or focal chest signs (one or more of the following):  * Nasal flaring * Chest retractions * Abdominal breathing * Focal dullness to percussion * Focal reduced breath sounds * Crackles with asymmetry |

**Outcome measures**

The primary outcome is clinically indicated treatment with systemic antibiotic other than trial medication for respiratory tract infection (including CAP) up to four weeks after randomisation. Reason and clinical indication are adjudicated by an Endpoint Review Committee (ERC), comprising independent and non-independent members. Independent members, including the ERC chair, are paediatricians independent of the trial and not involved in the clinical care of participants. Non-independent members include the Chief Investigator, project lead, and trial physician. ERC members review clinical narrative summaries of retreatment primary endpoint events, supportive data from patient trial diaries, unscheduled visit forms, and serious adverse event (SAE); they adjudicate whether additional antibiotics were prescribed due to CAP (early failure, relapse or recurrence), new bacterial infection (respiratory tract infection or other), intolerance of trial medication, or another reason. Final adjudication is based on consensus of the independent ERC members.

Secondary outcomes include (i) severity and duration of parent-reported CAP symptoms, (ii) specified amoxicillin-related adverse events (thrush, skin rashes, and diarrhoea), (iii) phenotypic resistance to penicillin at four weeks in nasopharyngeal *S. pneumoniae* isolates, and (iv) adherence to trial medication.

**Screening, randomisation, recruitment, and consent**

The trial flowchart is provided in Figure 2. Potential participants may require hospital admission for initial CAP management or may be discharged immediately from an ED or PAU. As antibiotic treatment duration is an eligibility criterion, additional eligibility assessment procedures are undertaken for those receiving antibiotics while in hospital; these differences are outlined in the following sections, and Figures 3 and 4.

***Screening***

Potential participants are identified and screened during initial clinical assessment. Participants discharged directly from an ED or PAU undergo all trial procedures prior to discharge. Children given antibiotics while in hospital have a secondary screening episode. Participating centres keep anonymised logs of screened children, including those who were not approached and those who declined participation, which are used to identify any issues for the trial, or at a given site.

***Consent***

Extensive information is available for recruiting sites, including printed and video materials (accessible at [www.capitstudy.org.uk](http://www.capitstudy.org.uk)); all materials have NHS Research Ethics Committee approval. Written informed consent is obtained by clinical or research staff from a parent/guardian after explanation of the aims, methods, benefits and potential hazards of the trial. Families may decline participation in all or any aspects of the trial, at any time and for any reason, without incurring any penalty or affecting treatment. Signed consent forms are kept by the site and a copy given to the family. A letter is sent to the General Practitioner (GP) informing them of the trial and the child's involvement.

***Enrolment process***

At enrolment, recruiting staff review trial materials with parents/guardians; these include a symptom diary, participant information sheet (PIS), investigational medicinal product (IMP) administration instructions, and contact details for the trial team. The symptom diary collects information on clinical and non-clinical elements including cough, breathing, temperature, adverse events, IMP administration, additional antibiotics, any other medication, time off work/childcare, and other health service use. Relevant elements are incorporated into baseline data collected by recruiting staff on enrolment clinical report forms (CRF). This is done with parents/guardians to facilitate their understanding of diary content; other baseline data include demographics, symptoms, underlying disease, antibiotic exposure in the preceding three months, chest findings, and Quality of Life (QoL) measures. Participants are registered on the online trial database; database access is controlled through authorised user names and passwords and all patient identifiable details are confidential.

A nasopharyngeal (NP) swab is collected at enrolment. *S. pneumoniae* is identifiedusing culture-based techniques, AMR is detected using Minimal Inhibitory Concentration (MIC) based techniques, and respiratory viruses are detected using molecular techniques. Stool and blood samples are collected in sites participating in ancillary studies, provided specific consent is given. There are no other mandatory radiological or laboratory tests; if done as part of routine clinical care, results of haematological, biochemical, and chest radiograph investigations are recorded.

***Randomisation***

Participants are allocated 1:1 to each of the two factorial randomisations, stratified according to whether or not they receive any non-trial antibiotics in hospital before being enrolled. A randomisation list is computer-generated based on random permuted blocks by the trial statistician. Based on this list, trial medication (including placebo) is labelled and packaged in a blinded manner by an independent supplier and delivered to trial sites; treatments are randomly assigned by taking the next sequentially numbered treatment from the relevant supply. As it is difficult to taste-match suspensions of amoxicillin and placebo, one brand of amoxicillin is used for all participants for the first three days, followed by a second bottle for days four to seven containing either a second brand of amoxicillin or placebo; both form a yellow-coloured similar tasting suspension, and parents are instructed to expect some change in taste after the first three days.

**Trial treatments**

Trial treatment starts on the day of enrolment, with the first dose given before discharge where possible. Children receive three or seven days of amoxicillin, and suspension is given twice daily with dosing by weight band; doses are 35-50mg/kg/day or 70-90mg/kg/day. To ensure blinding, amoxicillin suspensions of different strengths (125mg/5ml or 250mg/5ml) are used so that dose volume is the same regardless of treatment arm.

IMP is stored separately from routine medicines, and is dispensed in a box containing one bottle of amoxicillin and two bottles of either amoxicillin or placebo (blinded to contents). Colour-labels indicate which should be used on days one to three, and days four to seven. The importance of adherence is reinforced when dispensing IMP and during follow-up contacts. Adherence is assessed using the symptom diary, at telephone follow-up contacts, and at final follow-up when families return unused IMP.

IMP may be stopped early for reasons including toxicity, clinical change requiring treatment modification, or withdrawal of consent. All concomitant medications are allowed; if an essential medication interacts with amoxicillin, the IMP is stopped. Although participants are not required to give a reason for discontinuing IMP, a reasonable effort is made to establish this reason.

Situations necessitating unblinding are likely to be rare. Severe allergic reactions occur early during amoxicillin exposure; immediate discontinuation and trigger avoidance is recommended. Delayed reactions are generally mild and resolve with discontinuation. Where re-treatment is necessary, unblinding is unlikely to impact on antibiotic choice and is therefore unnecessary.If necessary, unblinding is done using an online emergency unblinding form.

**Follow up**

The trial assessment and follow-up schedule is shown in Figures 3 and 4. Telephone contact occurs on days four, eight to ten, 15-17 and 22-24; a face-to face visit occurs within two days of day 29. At each contact clinical signs and symptoms are reviewed, as are adverse treatment effects, acute illnesses requiring medical assessment, new antibiotics, and IMP adherence. At each face-to-face visit an NP swab is collected; if there are any CAP symptoms, examination findings and physiological parameters are recorded. If a face-to-face visit is not possible for final follow-up, it is attempted by telephone. If it is not possible to contact families despite reasonable efforts, relevant data are sought from the GP if consent has been given to do so.

Additional healthcare contacts may be necessary. Parents/guardians liaise with the site trial team if they are considering acute clinical assessment during the follow-up period, though they are advised to seek immediate emergency assessment if they feel this is required. Clinician judgement determines whether investigation, treatment or hospitalisation are required. Following any unscheduled assessment, symptoms, health service utilisation and IMP adherence are reviewed by telephone, and face-to-face visits arranged if necessary.

Parents/guardians who discontinue IMP are encouraged to adhere to the follow-up schedule, and the Sponsor is informed. If follow-up is stopped early, data already collected are kept for analysis, and the children are not replaced in the trial. Samples already obtained are processed unless parents/guardians request otherwise.

**Sample size and power**

The sample size is based on demonstrating non-inferiority for the primary endpoint for each duration and dose. Although inflation factors have been advocated for factorial trials to account for interaction between the interventions or a reduction in the number of events, this is not necessary if either randomised intervention has a null effect (the underlying hypothesis with a non-inferiority design), as marginal analyses can then be conducted. Assuming a 15% primary outcome event rate, 8% non-inferiority margin assessed against an upper one-sided 95% confidence interval (CI), 90% power, and 15% loss to follow-up, 800 children will be randomised. This is considered a minimum sample size; if resources permit, recruitment may continue above this number to increase statistical power and precisio, with the approval of the Trial Steering Committee (TSC).

**Analysis plan**

The primary analysis will be by modified intention-to-treat (ITT), including all participants who take at least one IMP dose. The primary endpoint will be analysed using time-to-event methods, controlling for previous antibiotic exposure. Potential interaction effects between dose, duration, and previous antibiotic exposure will be examined. For some secondary outcomes, including adverse events and resistance, on-treatment analyses will be performed as well as ITT analyses.

The primary analysis of the primary endpoint will include only clinically indicated additional systemic antibiotic for respiratory tract infection (including CAP) as adjudicated by the ERC. Sensitivity analyses will be performed to include (i) all systemic antibacterial treatments other than IMP regardless of reason and indication (to guard against bias), and (ii) only ERC-adjudicated clinically indicated systemic antibacterial treatment prescribed specifically for CAP (to provide clinical reassurance).

A subgroup analysis will consider CAP severity at presentation, and repeat the main efficacy analysis limited to participants with more severe disease. This will provide reassurance that an overall null effect (if observed) is not due to a dilution effect arising from inclusion of children with mild disease of viral aetiology, an important consideration as CAP is diagnosed clinically.

Lower dose and shorter duration will be considered “non-inferior” to higher dose and longer duration, respectively, if the upper limit of the one-sided 95% CI for the difference in the proportion of children with the primary endpoint at day 29 is less than the non-inferiority margin of 8%. However inference will be based primarily on point estimates and CIs rather than binary classification of a “non-inferior” or “not non-inferior” outcome.[42]

**Ancillary studies**

***Impact on gastrointestinal microflora***

Stool samples will be collected at enrolment and final follow-up from 200 children to evaluate the impact of amoxicillin exposure on different microbial communities, including AMR in gastrointestinal commensal flora. The baseline sample is collected prior to or as soon as possible after starting amoxicillin.

***Respiratory pathogen detection in blood***

In 50 children having blood tests for clinical care, 500 microlitres of blood will be used to assess whether respiratory pathogens can be detected using molecular assays; samples will be taken before commencing amoxicillin.

***Symptom diary completion methodology***

While widespread access to the internet and mobile devices suggest web-based questionnaires may be acceptable and reliable, data supporting this are lacking. As it is unclear which is best in terms of completion rates we will quasi-randomise participants to electronic or paper questionnaires based on gender and site. We will compare overall data completeness, and completeness of individual items between paper and electronic diaries. Data supporting use of one or other approach will be important for many trials eliciting primary or key secondary parent-reported outcomes through the use of symptom diaries.

**Safety reporting**

Definitions for adverse events (AE) and adverse reactions (AR) of the EU Directive 2001/20/EC Article 2 based on the principles of Good Clinical Practice (GCP) apply to this trial. The symptom diary prompts for known amoxicillin ARs including gastrointestinal symptoms and rash; AEs that lead to cessation of trial treatment are also reported. When an AE or AR occurs, the PI assesses whether this is a serious AE (SAE) using supplied definitions, and the level of severity using provided toxicity grading. Where an SAE has occurred, an SAE form is completed and the Sponsor notified within 24 hours of the PI becoming aware. Children are followed up after an SAE until complete clinical recovery or until the event has stabilised. Staff follow their institution’s procedure for local notification requirements. PIs assess causality of SAEs in relation to IMP; assessment of expectedness is completed based on common toxicities listed in the Summary of Product Characteristics; if a serious AR (SAR) is unexpected, the event is classified as a serious unexpected SAR (SUSAR) and reported to the Medicines and Healthcare products Regulatory Agency (MHRA), Research Ethics Committee (REC) and site PIs. Medically-qualified staff at the Sponsor and the CI (or medically-qualified delegate) review all SAE reports. In case of disagreement with regard to causality, both opinions are provided in any reports. All SAEs are reported to the MHRA and REC in the annual Development Safety Update Report.

**Trial monitoring**

Quality Assurance (QA) and Quality Control (QC) are based on a formal risk assessment (RA), to ensure all elements are performed in line with applicable regulatory requirements. Site initiation visits are done to deliver trial-specific training to key clinical and research personnel, which is cascaded to all relevant staff; training and delegation logs are monitored for completeness. Screening, randomisation, and consent rates are monitored by the trial team at MRC CTU at UCL, and data are checked for consistency, missing data points or possible errors, with suspect data returned as queries to ensure reliability and validity. PIs allow trial-related monitoring including audits, ethics committee review, and regulatory inspections, by providing direct access to source data and documents as required. The principles of the UK Data Protection Act (DPA) are followed.

The Trial Management Group (TMG) comprises the CI, clinical and non-clinical investigators, and the CAP-IT MRC CTU at UCL team. The TMG is responsible for the day-to-day running and management of the trial. The TSC has membership from the TMG plus independent members, including an Independent Chair, and provides overall guidance and advice. The Independent Data Monitoring Committee (IDMC) is the only group which sees confidential accumulating data for the trial by randomised group. Formal stopping rules are not used although the IDMC Charter specifies guidelines for when to alert the TSC to consider modifying the trial design. These guidelines are conservative to guard against premature changes to trial design from early inspection of the data.

**Regulatory compliance**

This trial is conducted in compliance with GCP principles as laid down by the Commission Directive 2005/28/EC, Statutory Instrument 2004 No 1031: Medicines for Human Use (Clinical Trials) Regulations 2004 as amended, the UK DPA (DPA number: Z5886415), and the NHS RGF for Health and Social Care. Sites inform the Sponsor as soon as they are aware of any possible serious breach of compliance, so that the Sponsor can report this as per regulatory requirements. This is a Clinical Trial of an IMP as defined by EU Directive 2001/20/EC. The CTA number is 17141803, and the EudraCT number is 2016-000809-36.

**ETHICS AND DISSEMINATION**

The protocol, PIS, consent form, and all relevant documentation were approved centrally by the National Research Ethics Service (NRES), West London & GTAC Research Ethics Committee (REC reference: 16/LO/0831; 30th June 2016). The results of the CAP-IT trial will be published in peer-reviewed journals read by health professionals managing childhood CAP in the UK and internationally, and in a report published by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme. To maximise impact internationally, oral and poster presentations will be given to relevant national and international conferences. Once the trial is completed, all participating families will be notified of the results if they wish. The social media presence of the organisations involved, including PERUKI (@PERUKItweep), will be utilised to disseminate key messages.

**DISCUSSION AND TRIAL STATUS**

The first participant was enrolled in February 2017; as of 31st January 2019, 690 patients have been enrolled from 30 sites. Recruitment is scheduled to finish in April 2019, and analysis to be completed by August 2019. The trial will end after the last follow-up visit of the last randomised participant.

Three significant changes to the CAP-IT analysis plan have been made during the course of the trial (Protocol Version 4.0, 4th December 2018) based on blinded emerging trial data. Firstly, although patients were originally intended to be stratified based on whether they received inpatient antibacterial treatment or were discharged directly from hospital, all patients will now be jointly analysed due to significant phenotypic overlap. Subgroup efficacy analyses will be performed to consider severity of CAP at presentation. Secondly, the primary endpoint definition has been made more specific from “all antibiotic prescriptions given during follow-up”, to “clinically indicated antibiotic prescriptions for respiratory tract infections (including CAP) as adjudicated by an ERC”. Finally, the non-inferiority margin was adjusted as the primary endpoint event rate had been substantially under-estimated.

The CAP-IT trial will provide important and robust evidence for amoxicillin treatment strategies for childhood CAP in developed settings post-PCV introduction. Its factorial nature will inform amoxicillin dose and duration, and the optimal regimen for minimal AMR selection. Combined with the results of ongoing trials (including SAFER[43] and SCOUT-CAP [accessible at https://clinicaltrials.gov/ct2/show/NCT02891915]) in similar healthcare systems, findings from the CAP-IT trial will improve and streamline cost-effective care on a global scale.[24]

The CAP-IT trial provides an important opportunity for learning and infrastructure development in acute paediatric trials in the UK & Ireland. Recruiting patients to a placebo-controlled randomised trial in EDs, PAUs, observation units, and inpatient wards has required close working across clinical (Emergency Medicine and General Paediatric) and research teams, and research networks. To date, successful recruitment has been led through close communication between the CTU and participating sites, with leadership from PERUKI, providing frequent opportunities to share best practice in overcoming any obstacles to trial delivery. This includes regular contact with sites, and a metaplanning exercise prior to the second winter of recruitment. Key obstacles identified included research training (GCP and study specific), out of hours recruitment, availability of site research staff, and delays to discharge caused by study processes. To overcome these, a number of new initiatives were developed, including streamlining of enrolment processes, to enable families to have the opportunity to participate in this important trial.

**Consent for publication**

Not applicable.

**Availability of data and materials**

Not applicable

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

The CAP-IT trial is funded by the NIHR HTA Programme, Antimicrobial Resistance Themed Call, via grant number 13/88/11. University College London (UCL) is the trial sponsor. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The trial funders and sponsor played no role in the trial design, writing the manuscript, or the decision to submit for publication; the responsibility for these actions lies with the Trial Management Group (TMG).

**Authors’ contributions**

MS devised the trial concept, and is the Chief Investigator. MS, DG, JB, ML, CP, AF, LH, DD, MW, PL, SF, JR, and AH secured the trial grant. MS, DG, JB, ML, AF, LH, and MW designed the clinical trial. CP, SF, AH, PL, SF, and JR contributed to the trial design and materials. PJ and KS contributed to the trial design and materials, and provided nursing leadership to participating sites. ML and DR were the PERUKI leads for the trial, and CP the GAPRUKI lead. DD and WS provided statistical input and developed the statistical analysis plan. SB and KS provided trial management. ML wrote the first draft of the manuscript with input from MS and DG; all authors contributed to subsequent drafts and agreed the final manuscript.

**Acknowledgements**

We thank all members of the trial committees, all families and children who have taken part, and all participating sites, for their invaluable contributions to the CAP-IT trial.

*Trial Steering Committee (TSC):* Elizabeth Molyneux (Chair), Chris Butler, Alan Smyth, Catherine Pritchard, Diana Gibb, Mike Sharland

*Independent Data Monitoring Committee (IDMC):* Tim Peto (Chair), Simon Cousens and Stuart Logan

*Independent Endpoint Review Committee (ERC) members:*Alasdair Bamford (Chair), Anna Turkova and Felicity Fitzgerald

*Trial Management Group (TMG):*Mike Sharland (Chair), Julia Bielicki, Mark Lyttle, Colin Powell, Paul Little, Saul Faust, Adam Finn, Julie Robotham, Mandy Wan, David Dunn, Wolfgang Stöhr, Lynda Harper, Sam Barratt, Nigel Klein, Louise Rogers, Elia Vitale and Diana Gibb

*MRC Clinical Trials Unit, UK:*Sam Barratt, Kate Sturgeon, Anna Griffiths, Jenna Grabey, Nishdha Naufal, Lynda Harper, , Wolfgang Stöhr, David Dunn, Vicky Yorke-Edwards, Jennifer Petrie and Diana Gibb

*Investigator Sites:*

Alder Hey Children’s Hospital NHS Foundation Trust, Liverpool: Dan Hawcutt (PI), Matt Rotheram, Liz D Lee and Rachel Greenwood-Bibby

Birmingham Children’s Hospital**:** Stuart Hartshorn (PI), Deepthi Jyothish, Louise Rogers and Juliet Hopkins

Bristol Royal Hospital for Children: Mark Lyttle (PI), Stefania Vergnano, Pauline Jackson, Beth Pittaway, Alice Smith, Michelle Ross, Lucie Aplin, Sarah Sheedy and Gurnie Kaur

Chelsea & Westminster NHS Foundation Trust, London: James Ross (PI), Poonam Patel, Nabila Burney, Hannah Fletcher, Jaime Carungcong, Kribashnie Nundlall

City Hospitals Sunderland NHS Foundation Trust: Niall Mullen (PI), Rhona McCrone and Paul P Corrigan

Countess of Chester Hospital:Susie Holt (PI), John Gibbs, Caroline Burchett, Caroline Lonsdale and Sarah De-Beger

Darlington Memorial Hospital**:** Godfrey Nyamugunuduru (PI), John Furness (former PI) and Dawn Eggington

Derbyshire Children’s Hospital, Derby**:** Gisela Robinson (PI), Lizzie Starkey and Mel Hayman

Evelina London Children’s Hospital:Anastasia Alcock (PI), Dani Hall (former PI), Ronny Cheung, Alyce B Sheedy and Mohammad Ahmad

James Cook University Hospital, Middlesbrough**:** Arshid Murad (PI), Katherine Jarman and Joanna Green

John Radcliffe Hospital, Oxford: Tanya Baron (PI), Chris Bird (former PI), Shelley Segal and Sally Beer

King’s College Hospital, London: Fleur Cantle (PI), Hannah Eastman, Raine Astin-Chamberlain, Paul Riozzi and Hannah Cotton

Leeds Children’s Hospital**:** Sean O’Riordan (PI), Alice Downes, Marjorie Allen and Louise Conner

Leicester Hospitals**:** Damian Roland (PI), Srini Bandi and Rekha Patel

Nottingham University Hospitals NHS Trust: Chris Gough (PI), Megan McAulay and Louise Conner

Southport and Ormskirk NHS Trust: Sharryn Gardner (PI), Zena Haslam, Moira Morrison

Our Lady’s Children’s Hospital Crumlin, Dublin**:** Michael Barrett (PI) and Madeleine Niermeyer

Royal Alexandra Children’s Hospital, Brighton**:** Emily Walton (PI), Akshat Kapur and Vivien Richmond

Royal Hospital for Children, Glasgow: Steven Foster (PI), Ruth Bland, Ashleigh Neil, Barry Milligan and Helen Bannister

Royal London Hospital**:** Ben Bloom (PI), Ami Parikh, Olivia Boulton, Imogen Skene

Royal Manchester Children’s Hospital:Katherine Potier (PI), Fiona Poole, Jill L Wilson

Sheffield Children’s Hospital NHS Foundation Trust: Judith Gilchrist (PI), Noreen West, Jayne Evans and Julie Morecombe

St George’s Hospital, London: Paul Heath (PI), Yasser Iqbal, Malte Kohns, Elena Stefanova, Elia Vitale

St Mary’s Hospital, London: Ian Maconochie (PI), Suzanne Laing, Rikke Jorgensen

University Hospitals Lewisham: Maggie Nyirenda (PI), Anastasia Alcock, Samia Pilgrim, Emma Gardiner

University Hospital of Wales, Cardiff: Jeff Morgan (PI), Colin VE Powell (former PI), Jennifer Muller and Gail Marshall

Southampton Children’s Hospital: Katrina Cathie (PI), Jane Bayreuther, Ruth Ensom, Emily Cornish

**REFERENCES**

1. Vaz LE, Kleinman KP, Raebel MA, et al. Recent Trends in Outpatient Antibiotic Use in Children. *Pediatrics* 2014;133(3):375-385.

2. Grijalva CG. Antibiotic Prescription Rates for Acute Respiratory Tract Infections in US Ambulatory Settings. *JAMA* 2009;302(7):758.

3. Hersh AL, Shapiro DJ, Pavia AT, et al. Antibiotic Prescribing in Ambulatory Pediatrics in the United States. *Pediatrics* 2011;128(6):1053–61.

4. Hay AD, Wilson A, Fahey T, et al. The duration of acute cough in pre-school children presenting to primary care: a prospective cohort study. *Fam Pract* 2003;20(6):696–705.

5. Sands R, Shanmugavadivel D, Stephenson T, et al. Medical problems presenting to paediatric emergency departments: 10 years on. *Emerg Med J* 2012;29(5):379–82.

6. Oostenbrink R, Thompson M, Lakhanpaul M, et al. Children with fever and cough at emergency care: diagnostic accuracy of a clinical model to identify children at low risk of pneumonia. *Eur J Emerg Med* 2013;20(4):273–80.

7. Donnelly JP, Baddley JW, Wang HE. Antibiotic Utilization for Acute Respiratory Tract Infections in US Emergency Departments. *Antimicrob Agents Chemother* 2014;58(3):1451–7.

8. Gill PJ, Goldacre MJ, Mant D, et al. Increase in emergency admissions to hospital for children aged under 15 in England, 1999–2010: national database analysis. *Arch Dis Child* 2013;98(5):328–34.

9. Brousseau DC, Nimmer MR, Yunk NL, et al. Nonurgent Emergency-Department Care: Analysis of Parent and Primary Physician Perspectives. *Pediatrics* 2011;127(2):e375–81.

10. Farha T, Thomson AH. The burden of pneumonia in children in the developed world. *Paediatr Respir Rev* 2005;6(2):76–82.

11. Lorgelly PK, Atkinson M, Lakhanpaul M, et al. Oral versus IV antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis. *Eur Respir J* 2010;35(4):858–64.

12. Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. *Thorax* 2011;66(Suppl 2):ii1–23.

13. Courtoy I, Lande AE, Turner RB. Accuracy of Radiographic Differentiation of Bacterial from Nonbacterial Pneumonia. *Clin Pediatr (Phila)* 1989;28(6):261–4.

14. Swingler GH. Radiologic Differentiation Between Bacterial and Viral Lower Respiratory Infection in Children: A Systematic Literature Review. *Clin Pediatr (Phila)* 2000;39(11):627-33

15. Cevey-Macherel M, Galetto-Lacour A, Gervaix A, et al. Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. *Eur J Pediatr* 2009;168(12):1429–36.

16. Honkinen M, Lahti E, Österback R, et al. Viruses and bacteria in sputum samples of children with community-acquired pneumonia. *Clin Microbiol Infect* 2012;18(3):300–7.

17. McEllistrem MC, Adams JM, Patel K, et al. Acute Otitis Media Due to Penicillin-Nonsusceptible Streptococcus pneumoniae Before and After the Introduction of the Pneumococcal Conjugate Vaccine. *Clin Infect Dis* 2005;40(12):1738–44.

18. Samore MH, Magill MK, Alder SC, et al. High Rates of Multiple Antibiotic Resistance inStreptococcus pneumoniae From Healthy Children Living in Isolated Rural Communities: Association With Cephalosporin Use and Intrafamilial Transmission. *Pediatrics* 2001;108(4):856–65.

19. Regev-Yochay G, Raz M, Dagan R, et al. Nasopharyngeal Carriage of Streptococcus pneumoniae by Adults and Children in Community and Family Settings. *Clin Infect Dis* 2004;38(5):632–9.

20. Dunais B, Pradier C, Carsenti Hé, et al. Influence of child care on nasopharyngeal carriage of streptococcus pneumoniae and haemophilus influenzae. *Pediatr Infect Dis J* 2003;22(7):589–93.

21. Lietzau S, Raum E, Baum H von, et al. Household contacts were key factor for children’s colonization with resistant Escherichia coli in community setting. *J Clin Epidemiol* 2007;60(11):1149–55.

22. Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. *Clin Infect Dis* 2011;53(7):e25–76.

23. WHO. Pocket book of hospital care for children: Second Edition. Guidelines for the management of common conditions. WHO 2013.

24. Mathur S, Fuchs A, Bielicki J, et al. Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review. *Paediatr Int Child Health* 2018;38(sup1):S66–75.

25. Appelbaum PC. Microbiological and Pharmacodynamic Considerations in the Treatment of Infection Due to Antimicrobial-Resistant Streptococcus pneumoniae. *Clin Infect Dis* 2000 ;31(Supplement):S29–34.

26. Calbo E, Garau J. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections. *Respiration* 2005;72(6):561–71.

27. Lassi ZS, Das JK, Haider SW, et al. Systematic review on antibiotic therapy for pneumonia in children between 2 and 59 months of age. *Arch Dis Child* 2014;99(7):687–93.

28. Chorazy ML, Lebeck MG, McCarthy TA, et al. Polymicrobial Acute Respiratory Infections in a Hospital-based Pediatric Population. *Pediatr Infect Dis J* 2013;32(5):460–6.

29. Greenberg D, Givon-Lavi N, Sadaka Y, et al. Short-course Antibiotic Treatment for Community-acquired Alveolar Pneumonia in Ambulatory Children: A Double-blind, Randomized, Placebo-controlled Trial. *Pediatr Infect Dis J* 2014;33(2):136–42.

30. Esposito S, Cohen R, Domingo JD, et al. Do We Know When, What and For How Long to Treat? Antibiotic Therapy for Pediatric Community-acquired Pneumonia. *Pediatr Infect Dis J* 2012;31(6).

31. Atkinson M, Lakhanpaul M, Smyth A, et al. Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial. *Thorax* 2007;62(12):1102–6.

32. Thompson M, Vodicka TA, Blair PS, et al. Duration of symptoms of respiratory tract infections in children: systematic review. *BMJ* 2013;347:f7027.

33. Currie CJ, Berni E, Jenkins-Jones S, et al. Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis. *BMJ* 2014;349:g5493.

34. Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. *BMJ* 2010;340:c2096.

35. Raum E, Lietzau S, von Baum H, et al. Changes in E. coli resistance patterns during and after antibiotic therapy: a longitudinal study among outpatients in Germany. *Clin Microbiol Infect* 2008;14(1):41–8.

36. Guillemot D, Carbon C, Balkau B, et al. Low Dosage and Long Treatment Duration of β-Lactam: Risk Factors for Carriage of Penicillin-Resistant Streptococcus pneumoniae. *JAMA* 1998;279(5):365.

37. Schrag SJ, Peña C, Fernández J, et al. Effect of Short-Course, High-Dose Amoxicillin Therapy on Resistant Pneumococcal Carriage: A Randomized Trial. *JAMA* 2001;286(1):49.

38. Tam VH, Louie A, Fritsche TR, et al. Impact of Drug-Exposure Intensity and Duration of Therapy on the Emergence of Staphylococcus aureus Resistance to a Quinolone Antimicrobial. *J Infect Dis* 2007;195(12):1818–27.

39. Opatowski L, Mandel J, Varon E, et al. Antibiotic Dose Impact on Resistance Selection in the Community: a Mathematical Model of β-Lactams and Streptococcus pneumoniae Dynamics. *Antimicrob Agents Chemother* 2010;54(6):2330–7.

40. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. *Ann Intern Med* 2013;158(3):200–7.

41. Lyttle MD, O’Sullivan R, Hartshorn S, et al. Pediatric Emergency Research in the UK and Ireland (PERUKI): developing a collaborative for multicentre research. *Arch Dis Child* 2014;99(6):602–3.

42. Dunn DT, Copas AJ, Brocklehurst P. Superiority and non-inferiority: two sides of the same coin? *Trials* 2018;19:499.

43. Pernica J, Harman S, Kam A, et al. Short-course antimicrobial therapy for paediatric respiratory infections (SAFER): study protocol for a randomized controlled trial. *Trials*. 2018;19(1):83.

**Figures – captions and legends**

**Figure 1. Possible treatment arms in the CAP-IT trial**

**Figure 2: CAP-IT Trial flowchart**

**Figure 3: CAP-IT Trial Schema**

**Figure 4: CAP-IT trial assessment schedule**

*(X) indicates tests that may be done if the child's condition requires it or allows it, but are not mandatory; \*Assessments in this column only undertaken for potential participants receiving inpatient antibiotic treatment; †may be done any time before enrolment discussion; ‡taken before starting antibiotics where possible*